Nature Metabolism reports that lipid mixtures found in ovarian cancer patient ascites can impair T-cell activation by disturbing T-cell receptor (TCR) dynamics. Instead of acting like classic checkpoint inhibitors or cytokine blockers, the study shows that membrane lipids can interfere with how TCR-related processes operate at the cell surface. The results provide a more granular immune-suppression mechanism tied to the tumor microenvironment’s biochemical composition. For immunotherapy development, it suggests lipid-targeted strategies may complement existing approaches in ovarian cancer where T-cell dysfunction is a major obstacle.